论文部分内容阅读
目的综述近年来抗心力衰竭药物基因组学研究进展。方法查阅国内外相关文献,并进行总结归纳。结果血管紧张素转换酶、缓激肽β2受体、细胞色素P450酶、β肾上腺素受体、G蛋白偶联受体激酶、多药耐药蛋白等的基因多态性与抗心力衰竭药物的药效差异有直接关系。结论从基因的角度解释相同疗法在不同心肌衰竭患者间的疗效、不良反应差异,从而更好地指导临床实现个体化给药,提高药物疗效、减少毒副反应。
Objective To summarize the research progress of anti-heart failure drug genomics in recent years. Methods Access to relevant literature at home and abroad, and to summarize. Results The genetic polymorphisms of angiotensin-converting enzyme, bradykinin β2 receptor, cytochrome P450 enzyme, β-adrenergic receptor, G protein-coupled receptor kinase, multidrug resistance protein and other anti-heart failure drugs The difference is directly related to the efficacy. Conclusion The explanation of the same therapy in different myocardial failure patients from the perspective of gene therapy, adverse reactions, to better guide the clinical implementation of individualized administration, improve drug efficacy and reduce side effects.